- Home
- ACET vs RAND Comparison
ACET vs RAND Comparison
Compare ACET & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- RAND
- Stock Information
- Founded
- ACET 1947
- RAND 1969
- Country
- ACET United States
- RAND United States
- Employees
- ACET N/A
- RAND N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- ACET Health Care
- RAND Finance
- Exchange
- ACET Nasdaq
- RAND Nasdaq
- Market Cap
- ACET 44.4M
- RAND 52.9M
- IPO Year
- ACET N/A
- RAND N/A
- Fundamental
- Price
- ACET $0.60
- RAND $19.80
- Analyst Decision
- ACET Buy
- RAND
- Analyst Count
- ACET 6
- RAND 0
- Target Price
- ACET $6.00
- RAND N/A
- AVG Volume (30 Days)
- ACET 523.1K
- RAND 8.3K
- Earning Date
- ACET 05-13-2025
- RAND 05-12-2025
- Dividend Yield
- ACET N/A
- RAND 25.61%
- EPS Growth
- ACET N/A
- RAND 35.26
- EPS
- ACET N/A
- RAND 3.42
- Revenue
- ACET N/A
- RAND $8,559,285.00
- Revenue This Year
- ACET N/A
- RAND N/A
- Revenue Next Year
- ACET N/A
- RAND N/A
- P/E Ratio
- ACET N/A
- RAND $5.73
- Revenue Growth
- ACET N/A
- RAND 16.64
- 52 Week Low
- ACET $0.45
- RAND $13.69
- 52 Week High
- ACET $2.08
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- ACET 43.47
- RAND 51.16
- Support Level
- ACET $0.51
- RAND $18.85
- Resistance Level
- ACET $0.61
- RAND $21.30
- Average True Range (ATR)
- ACET 0.07
- RAND 1.55
- MACD
- ACET 0.01
- RAND 0.33
- Stochastic Oscillator
- ACET 55.54
- RAND 70.53
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.